Results of a clinical trial show that men with prostate cancer who are treated with intermittent courses (known as a drug holiday) of androgen-suppressing therapy will live as long as those receiving continuous therapy. The trial was led by the NCIC Clinical Trials Group, which is funded by the Canadian Cancer Society. It found that not only do the men live as long, they may also experience greater quality of life with fewer uncomfortable side effects from continuous exposure to androgen-suppressing therapy. Read more here.
Study mentioned: Crook JM, et al. Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. N Engl J Med. 2012 Sep 6;367(10):895-903. PMID: 22931259
No comments:
Post a Comment